Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue , 2015, Pages

  Harvey, Christopher ^a   Elpek, Kutlu ^a   Duong, Ellen ^a   Simpson, Tyler ^a   Shu, ChengYi J ^a   Shallberg, Lindsey ^a   Wallace, Matthew ^a   Sathyanarayanan, Sriram ^a   Mabry, Robert ^a   Briskin, Michael ^a   Michaelson, Jennifer ^a   Gajewski, Thomas F ^b  

^a Jounce Therapeutics   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY; TUMOR CELL VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL OUTCOME; HUMAN; MELANOMA B16; PRECLINICAL STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UPREGULATION;

EID: 85029269598     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-3-S2-O9     Document Type: Article

References (0)